TY - JOUR
T1 - An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms
T2 - An overview of previous and ongoing studies with perspectives on the future
AU - Qin, Albert
AU - Urbanski, Raymond W.
AU - Yu, Lennex
AU - Ahmed, Tasfia
AU - Mascarenhas, John
N1 - Funding Information:
The authors thank Jewell Jessup, PhD and Megan Flynn, PhD for providing considerate comments and editorial assistance.
Publisher Copyright:
Copyright © 2023 Qin, Urbanski, Yu, Ahmed and Mascarenhas.
PY - 2023/1/19
Y1 - 2023/1/19
N2 - Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.
AB - Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.
KW - alternative dosing strategy
KW - clinical study
KW - interferon
KW - myeloproliferative neoplasm
KW - pegylated interferon
KW - polycythemia vera
KW - ropeginterferon alfa-2b
UR - http://www.scopus.com/inward/record.url?scp=85147908098&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1109866
DO - 10.3389/fonc.2023.1109866
M3 - Article
AN - SCOPUS:85147908098
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1109866
ER -